PROMOTING ACCESS TO AFRICAN RESEARCH

African Health Sciences

Log in or Register to get access to full text downloads.

Remember me or Register



CA 125 is a better marker to differentiate endometrial cancer and abnormal uterine bleeding

Nithin U Kumar, M G Sridhar, K Srilatha, S Habebullah

Abstract


Background: Incidence of endometrial cancer in India is increasing due to lifestyle changes and obesity. As 5 year survival rate of cancer confined to uterus is good, there is need for serum tumor marker for early diagnosis. This study was designed to identify a tumor marker which differentiate endometrial carcinoma and abnormal uterine bleeding (AUB) because common presentation of endometrial carcinoma is AUB.
Objectives: To estimate and compare serum prolactin, Cancer Antigen 125 (CA-125), Cancer Antigen 15-3 (CA15-3), and Carcino embryonic antigen (CEA) levels in patients with endometrial cancer and abnormal uterine bleeding; To evaluate the role of these markers in diagnosing endometrial cancer.
Methodology: Thirty eight patients with endometrial cancer and 40 patients with AUB were recruited in this study. Serum prolactin, CA 125, CEA, and CA 15-3 levels were estimated in both groups.
Results: The levels of CA 15-3, CA 125, CEA, and prolactin were increased in endometrial carcinoma patients, on comparison with AUB patients. CA 125 alone was found to be a better marker to detect endometrial cancer with 52.63% sensitivity, 80.00% specificity.
Conclusion: As individual tumor marker, serum CA 125 has the ability to detect endometrial cancer in patients with abnormal uterine bleeding.

Keywords: CA-125 antigen, CA 15-3, carcino embryonic antigen, endometrial carcinoma, prolactin, tumor marker, abnormal uterine bleeding.




AJOL African Journals Online